Trevi Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Trevi Therapeutics (NASDAQ:TRVI) reported Q4 earnings, beating estimated earnings by 11.0% with an EPS of $-0.08 versus an estimate of $-0.09. However, revenue was unchanged from the same period last year. In the previous quarter, the company also beat EPS estimates, which was followed by a 3.0% drop in share price the next day.
March 20, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Trevi Therapeutics reported a better-than-expected Q4 earnings with an EPS of $-0.08, surpassing estimates by 11%. Despite this, revenue remained unchanged from the previous year. Historically, a beat in earnings last quarter resulted in a 3% drop in share price the following day.
While Trevi Therapeutics exceeded earnings expectations, the unchanged revenue and historical share price drop following last quarter's earnings beat suggest a neutral short-term impact. Investors may react cautiously given the previous price drop post-earnings beat.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100